Literature DB >> 21605905

Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?

Ahmet Emre Eskazan, Teoman Soysal, Yucel Erbilgin, Ugur Ozbek, Burhan Ferhanoglu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21605905     DOI： 10.1016/j.leukres.2011.04.025

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  2 in total

1.  Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.

Authors:  Ahmet Emre Eşkazan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

Review 2.  Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Authors:  Dilek Keskin; Sevil Sadri; Ahmet Emre Eskazan
Journal:  Drug Des Devel Ther       Date:  2016-10-13       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.